Breakthrough Product Approved! D-shufo™ PFO Occluder Launches Recruitment Drive, Ushering in a New Era of Collaboration

Feb 22, 2024 19:43 CST Updated 19:43

Vickor

Structural Heart Disease Minimally Invasive Intervention Product Developer

Wuhan Vickor Medical Technology Co., Ltd.'s self-developedD-shufo™ New Generation PFO Occluder Recently Approved by China's National Medical Products Administration (NMPA)MPA) Registration Approval.D-shufo™ PFO Occluder, as the second domestically produced nickel-titanium alloy PFO occluder approved for marketing in China, is also currently the PFO occluder with the most comprehensive specifications available on the market.

What is Patent Foramen Ovale (PFO)?

The Foramen Ovale: A Natural Passage in the Heart with Potential Health Implications

In recent years, with the deepening research on PFO, more and more clinical syndromes have been associated with it, including cryptogenic stroke, transient ischemic attack, and migraine. Particularly in cases of cryptogenic stroke and migraine, studies have found that compared to individuals without PFO, patients with PFO face significantly increased risks of stroke, migraine, and other conditions. These health issues not only cause immense physical and psychological suffering for patients but also impose a heavy burden on families and society.

To effectively address these issues, percutaneous interventional closure of the patent foramen ovale (PFO) has become a clinically recognized treatment method aimed at preventing the recurrence of stroke events and reducing the frequency of migraine attacks. In 2023, the annual number of PFO closure procedures reached 60,000 cases, showing a steadily increasing trend each year.

D-shufo™ New Generation PFO Occluder

D-shufo™ Occluder has been meticulously optimized in both structure and material processing, demonstrating strong technical capabilities.

Its unique disc-shaped concave plate design effectively increases the success rate of treatment, bringing better rehabilitation hope to patients. In terms of material selection, the D-shufo™ occluder adopts high-quality nickel-titanium alloy, which has been clinically verified for over 20 years to ensure long-term effectiveness. It is worth mentioning that the parylene coating covering the surface of the occluder effectively reduces the release of nickel ions, further enhancing the reliability of the product.

The launch of the D-shufo™ occluder not only demonstrates China's innovative strength in the medical device field but also represents a new phase in the treatment of patent foramen ovale (PFO) in China. Its excellent performance and unique design provide a standardized, high-quality new option for the clinical treatment of PFO, opening a new chapter in treatment.

- END -